Skip to content

EBITDA at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$111.74M-55.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$23.99M+10.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$129.48M+5.3%
uniQure logo
uniQureQURE
-$42.76M-22.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.24M+83.0%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

$130.4Mebit+
$2.4MDepreciation Depletion & Amortization
=-$128.06M

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's EBITDA?
Biohaven (BHVN) reported EBITDA of -$128.06M in Q1 2026.
How has Biohaven's EBITDA changed year-over-year?
Biohaven's EBITDA increased by 41.6% year-over-year, from -$219.32M to -$128.06M.
What is the long-term trend for Biohaven's EBITDA?
Over 3 years (2022 to 2025), Biohaven's EBITDA has grown at a 9.1% compound annual growth rate (CAGR), from -$566.55M to -$735.46M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.